Antinociceptive and Immune Effects of Delta-9-Tetrahydrocannabinol or Cannabidiol in Male Versus Female Rats with Persistent Inflammatory Pain

Britch, Stevie C; Goodman, Alan G.; Wiley, Jenny L.; Pondelick, Abby M.; Craft, Rebecca M.

doi:10.1124/jpet.119.263319

Cited by 59 publications

(52 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Each value is the mean of duplicate determinations. Eurofins Panlabs criteria for significance in this assay are set at >50% binding inhibition others have reported that CBD attenuates the release of a wide range of pro-inflammatory mediators in other rodent models of pain (Britch et al, 2020;Li et al, 2018;Linher-Melville et al, 2020). It remains to be determined whether KLS-13019 is working through CBD-like antiinflammatory mechanisms in this model or through a unique pathway similar to its effects on the reversal of paclitaxel-induced mechanical sensitivity.…”

Section: Discussionmentioning

confidence: 99%

Behavioural and pharmacological effects of cannabidiol (CBD) and the cannabidiol analogue KLS‐13019 in mouse models of pain and reinforcement

Foss

Farkas

Huynh

et al. 2021

British J Pharmacology

View full text Add to dashboard Cite

Background and Purpose: Cannabidiol (CBD) is a non-euphorigenic component of Cannabis sativa that prevents the development of paclitaxel-induced mechanical sensitivity in a mouse model of chemotherapy-induced peripheral neuropathy (CIPN).We recently reported that the CBD structural analogue KLS-13019 shows efficacy in an in vitro model of CIPN. The present study was to characterize the behavioural effects of KLS-13019 compared to CBD and morphine in mouse models of CIPN, nociceptive pain and reinforcement.Experimental Approach: Prevention or reversal of paclitaxel-induced mechanical sensitivity were assessed following intraperitoneal or oral administration of CBD, KLS-13019 or morphine. Antinociceptive activity using acetic acid-induced stretching and hot plate assay, anti-reinforcing effects on palatable food or morphine selfadministration and binding to human opioid receptors were also determined.

show abstract

Section: Discussionmentioning

confidence: 99%

Behavioural and pharmacological effects of cannabidiol (CBD) and the cannabidiol analogue KLS‐13019 in mouse models of pain and reinforcement

Foss

Farkas

Huynh

et al. 2021

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…In turn, CBD i.p. administration had minimal effects on inflammatory pain but significantly reduced interleukin 1β (IL-1β), IL-10, interferon γ (IFN-γ) levels and increased IL-6 levels [ 82 ]. This result suggests a more beneficial role for Δ9-THC compared to CBD in pain attenuation due to the ambiguous results in inflammatory-related factor levels in the serum.…”

Section: The Analgesic Potential Of Cbdmentioning

confidence: 99%

Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action

Mlost

Bryk

Starowicz

2020

IJMS

198

143

View full text Add to dashboard Cite

Cannabis has a long history of medical use. Although there are many cannabinoids present in cannabis, Δ9tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) are the two components found in the highest concentrations. CBD itself does not produce typical behavioral cannabimimetic effects and was thought not to be responsible for psychotropic effects of cannabis. Numerous anecdotal findings testify to the therapeutic effects of CBD, which in some cases were further supported by research findings. However, data regarding CBD’s mechanism of action and therapeutic potential are abundant and omnifarious. Therefore, we review the basic research regarding molecular mechanism of CBD’s action with particular focus on its analgesic potential. Moreover, this article describes the detailed analgesic and anti-inflammatory effects of CBD in various models, including neuropathic pain, inflammatory pain, osteoarthritis and others. The dose and route of the administration-dependent effect of CBD, on the reduction in pain, hyperalgesia or allodynia, as well as the production of pro and anti-inflammatory cytokines, were described depending on the disease model. The clinical applications of CBD-containing drugs are also mentioned. The data presented herein unravel what is known about CBD’s pharmacodynamics and analgesic effects to provide the reader with current state-of-art knowledge regarding CBD’s action and future perspectives for research.

show abstract

“…The two receptors exert distinct functions via specific signaling pathways, and different cannabinoids can activate them to various degrees; therefore, cannabinoids can vary in terms of effectiveness and potency [38]. While some anti-inflammatory properties were also described for CB1-specific agonists, their effects may also be carried through non-CB1non-CB2 signaling, and their most common usage is the management of pain, in which they prove highly effective [39,40]. Conversely, CB2 receptors are mainly involved in regulating inflammation by modulating the levels of various cytokines [41].…”

Section: Cannabinoids and Inflammationmentioning

confidence: 99%

Cannabinoids and Inflammations of the Gut-Lung-Skin Barrier

Scheau

Căruntu

Bădărău

et al. 2021

JPM

View full text Add to dashboard Cite

Recent studies have identified great similarities and interferences between the epithelial layers of the digestive tract, the airways and the cutaneous layer. The relationship between these structures seems to implicate signaling pathways, cellular components and metabolic features, and has led to the definition of a gut-lung-skin barrier. Inflammation seems to involve common features in these tissues; therefore, analyzing the similarities and differences in the modulation of its biomarkers can yield significant data promoting a better understanding of the particularities of specific signaling pathways and cellular effects. Cannabinoids are well known for a wide array of beneficial effects, including anti-inflammatory properties. This paper aims to explore the effects of natural and synthetic cannabinoids, including the components of the endocannabinoid system, in relation to the inflammation of the gut-lung-skin barrier epithelia. Recent advancements in the use of cannabinoids as anti-inflammatory substances in various disorders of the gut, lungs and skin are detailed. Some studies have reported mixed or controversial results, and these have also been addressed in our paper.

show abstract

Antinociceptive and Immune Effects of Delta-9-Tetrahydrocannabinol or Cannabidiol in Male Versus Female Rats with Persistent Inflammatory Pain

Cited by 59 publications

References 56 publications

Behavioural and pharmacological effects of cannabidiol (CBD) and the cannabidiol analogue KLS‐13019 in mouse models of pain and reinforcement

Behavioural and pharmacological effects of cannabidiol (CBD) and the cannabidiol analogue KLS‐13019 in mouse models of pain and reinforcement

Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action

Cannabinoids and Inflammations of the Gut-Lung-Skin Barrier

Contact Info

Product

Resources

About